<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02094586</url>
  </required_header>
  <id_info>
    <org_study_id>PXVX-VC-200-004</org_study_id>
    <nct_id>NCT02094586</nct_id>
  </id_info>
  <brief_title>A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults</brief_title>
  <official_title>Phase 3 Randomized, Double-blind, Placebo-Controlled 3-Lot Study in Healthy Volunteers to Assess Immunogenicity, &amp; Acceptability of a Single-dose of Live Oral Cholera Vaccine, Vibrio Cholerae O1 Serotype Inaba Vaccine Strain CVD 103-HgR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this Phase III study is to compare 3 lots for consistency of manufacture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary goal of this Phase III study is to compare three lots for consistency of&#xD;
      manufacture.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and B</measure>
    <time_frame>Day 11</time_frame>
    <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5. Placebo GMT values were not included in the primary analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots B and C</measure>
    <time_frame>Day 11</time_frame>
    <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and C</measure>
    <time_frame>Day 11</time_frame>
    <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVA Seroconversion at Day 11</measure>
    <time_frame>Day 11</time_frame>
    <description>Percentage of subjects who demonstrated a ≥4-fold rise over baseline in serum vibriocidal antibody (SVA) at Day 11</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVA and Anti-CT IgG GMT at Day 1, 11, 29, 91 and 181</measure>
    <time_frame>Day 1 - 181</time_frame>
    <description>GMTs of vibriocidal antibody and anti-CT IgG concentrations at Days 1, 11, 29, 91, and 181.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SVA and Anti-CT IgG Seroconversion at Day 1, 11, 29, 91 &amp; 181</measure>
    <time_frame>Day 1 - 181</time_frame>
    <description>Proportion of subjects who demonstrated a ≥4-fold rise over baseline in vibriocidal antibody and anti-CT IgG concentration from baseline at Days 1, 11, 29, 91, and 181. Day 1 not reported as seroconversion on Day 1 not applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Day 1 - 29</time_frame>
    <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, fever &amp; vomiting were collected from Day 1 - 8.&#xD;
Incidence and severity of unsolicited adverse events were collected till Day 29.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3146</enrollment>
  <condition>Cholera</condition>
  <arm_group>
    <arm_group_label>PXVX0200 Lot A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; &gt; 2x10^8 CFU in a liquid suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXVX0200 Lot B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; &gt; 2x10^8 CFU in a liquid suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PXVX0200 Lot C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; &gt; 2x10^8 CFU in a liquid suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200 Lot A</intervention_name>
    <description>Lot P700-1CA03</description>
    <arm_group_label>PXVX0200 Lot A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200 Lot B</intervention_name>
    <description>Lot P700-3CA03</description>
    <arm_group_label>PXVX0200 Lot B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PXVX0200 Lot C</intervention_name>
    <description>Lot P700-6BA03</description>
    <arm_group_label>PXVX0200 Lot C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy men or women,&#xD;
&#xD;
          -  age 18 to 45 years inclusive;&#xD;
&#xD;
          -  normal medical history and physical examination&#xD;
&#xD;
          -  Women must have a negative pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  travel to a cholera endemic area in the previous 5 years;&#xD;
&#xD;
          -  abnormal stool pattern or regular use of laxatives;&#xD;
&#xD;
          -  Currently active unstable or undiagnosed medical conditions&#xD;
&#xD;
          -  current or recent antibiotic use;&#xD;
&#xD;
          -  pregnancy or nursing;&#xD;
&#xD;
          -  Previously received a licensed or investigational cholera vaccine&#xD;
&#xD;
          -  History of cholera or enterotoxigenic E. coli infection&#xD;
&#xD;
          -  History of Guillain-Barré Syndrome&#xD;
&#xD;
          -  Received or plans to receive any other licensed vaccines, except for seasonal&#xD;
             influenza&#xD;
&#xD;
          -  Recipient of bone marrow or solid organ transplant&#xD;
&#xD;
          -  Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders&#xD;
             diagnosed or treated during the past 5 years&#xD;
&#xD;
          -  Use of systemic chemotherapy in the previous 5 years prior to the study&#xD;
&#xD;
          -  any immunosuppressive medical condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCarty, MD</last_name>
    <role>Study Director</role>
    <affiliation>Emergent Travel Health Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Reseach Consortium Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avail Clinical Research</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palm Beach Research</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Consortium Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rochester Clinical Research</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lion Research</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QIMR Berghofer Medical Research Institiue</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUS Trials Pty Ltd</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emeritis Research</name>
      <address>
        <city>Malvern East</city>
        <state>Victoria</state>
        <zip>3145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>McCarty JM, Lock MD, Hunt KM, Simon JK, Gurwith M. Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR in healthy adults age 18-45. Vaccine. 2018 Feb 1;36(6):833-840. doi: 10.1016/j.vaccine.2017.12.062. Epub 2018 Jan 6.</citation>
    <PMID>29317118</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>March 20, 2014</study_first_submitted>
  <study_first_submitted_qc>March 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2014</study_first_posted>
  <results_first_submitted>July 3, 2018</results_first_submitted>
  <results_first_submitted_qc>June 24, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholera</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Following assignment to either receive PXVX0200 or placebo, subjects in the PXVX0200 arm were randomized to receive Lot A, B or C. Subjects in each of these Arms/Groups add up to the number of subjects in the PXVX0200 (Lot A, B and C) Arm/Group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PXVX0200 Lot A</title>
          <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="P2">
          <title>PXVX0200 Lot B</title>
          <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="P3">
          <title>PXVX0200 Lot C</title>
          <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo physiological saline&#xD;
Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="927"/>
                <participants group_id="P2" count="933"/>
                <participants group_id="P3" count="935"/>
                <participants group_id="P4" count="351"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="848"/>
                <participants group_id="P2" count="866"/>
                <participants group_id="P3" count="876"/>
                <participants group_id="P4" count="331"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="59"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PXVX0200 Lot A</title>
          <description>PXVX0200 (Lot P700-1CA03) Single dose; liquid suspension after reconstitution with buffer; &gt; 2x10^8 CFU in a liquid suspension</description>
        </group>
        <group group_id="B2">
          <title>PXVX0200 Lot B</title>
          <description>PXVX0200 (Lot P700-3CA03) Single dose; liquid suspension after reconstitution with buffer; &gt; 2x10^8 CFU in a liquid suspension</description>
        </group>
        <group group_id="B3">
          <title>PXVX0200 Lot C</title>
          <description>PXVX0200 (Lot P700-6BA03) Single dose; liquid suspension after reconstitution with buffer; &gt; 2x10^8 CFU in a liquid suspension</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo physiological saline</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="927"/>
            <count group_id="B2" value="933"/>
            <count group_id="B3" value="935"/>
            <count group_id="B4" value="351"/>
            <count group_id="B5" value="3146"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Between 18 and 45 years inclusive</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="927"/>
                    <measurement group_id="B2" value="933"/>
                    <measurement group_id="B3" value="935"/>
                    <measurement group_id="B4" value="351"/>
                    <measurement group_id="B5" value="3146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.8" spread="7.78"/>
                    <measurement group_id="B2" value="29.9" spread="7.54"/>
                    <measurement group_id="B3" value="30.2" spread="7.72"/>
                    <measurement group_id="B4" value="29.5" spread="7.54"/>
                    <measurement group_id="B5" value="29.9" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="510"/>
                    <measurement group_id="B2" value="503"/>
                    <measurement group_id="B3" value="514"/>
                    <measurement group_id="B4" value="155"/>
                    <measurement group_id="B5" value="1682"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="417"/>
                    <measurement group_id="B2" value="430"/>
                    <measurement group_id="B3" value="421"/>
                    <measurement group_id="B4" value="196"/>
                    <measurement group_id="B5" value="1464"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="222"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="231"/>
                    <measurement group_id="B4" value="115"/>
                    <measurement group_id="B5" value="806"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="649"/>
                    <measurement group_id="B2" value="626"/>
                    <measurement group_id="B3" value="655"/>
                    <measurement group_id="B4" value="218"/>
                    <measurement group_id="B5" value="2148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="809"/>
                    <measurement group_id="B2" value="805"/>
                    <measurement group_id="B3" value="817"/>
                    <measurement group_id="B4" value="300"/>
                    <measurement group_id="B5" value="2731"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="118"/>
                    <measurement group_id="B2" value="128"/>
                    <measurement group_id="B3" value="118"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and B</title>
        <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5. Placebo GMT values were not included in the primary analysis.</description>
        <time_frame>Day 11</time_frame>
        <population>The Immunogenicity Evaluable Population (IEP) comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200 Lot A</title>
            <description>A single dose PXVX0200; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>PXVX0200 Lot B</title>
            <description>A single dose PXVX0200; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and B</title>
          <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5. Placebo GMT values were not included in the primary analysis.</description>
          <population>The Immunogenicity Evaluable Population (IEP) comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity.</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="892"/>
                <count group_id="O2" value="887"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9220" lower_limit="8219" upper_limit="10343"/>
                    <measurement group_id="O2" value="10034" lower_limit="8942" upper_limit="11260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Lot A vs. Lot B</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The GMT of each lot was required to be within ±50% of each other lot with 95% confidence. Specifically, the 95% CI around each pairwise ratio of GMTs was required to be within [0.67, 1.5].</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVA Seroconversion at Day 11</title>
        <description>Percentage of subjects who demonstrated a ≥4-fold rise over baseline in serum vibriocidal antibody (SVA) at Day 11</description>
        <time_frame>Day 11</time_frame>
        <population>IEP - comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200 Lot A</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>PXVX0200 Lot B</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O3">
            <title>PXVX0200 Lot C</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>SVA Seroconversion at Day 11</title>
          <description>Percentage of subjects who demonstrated a ≥4-fold rise over baseline in serum vibriocidal antibody (SVA) at Day 11</description>
          <population>IEP - comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="892"/>
                <count group_id="O2" value="887"/>
                <count group_id="O3" value="909"/>
                <count group_id="O4" value="334"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94" lower_limit="92" upper_limit="96"/>
                    <measurement group_id="O2" value="93" lower_limit="91" upper_limit="94"/>
                    <measurement group_id="O3" value="94" lower_limit="92" upper_limit="95"/>
                    <measurement group_id="O4" value="4" lower_limit="2" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVA and Anti-CT IgG GMT at Day 1, 11, 29, 91 and 181</title>
        <description>GMTs of vibriocidal antibody and anti-CT IgG concentrations at Days 1, 11, 29, 91, and 181.</description>
        <time_frame>Day 1 - 181</time_frame>
        <population>The subgroup examining long-term and specific functional immunogenicity was formed to examine specific behavior of Vaxchora based a smaller total sample size than the total study due to the complexity of the assays needed for the endpoints. As such, an analysis by lot would have rendered any examination severely underpowered and was not necessary due to the objective to examine Vaxchora vs placebo rather than the affect of lot on those endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200 (Lot A, B and C)</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>SVA and Anti-CT IgG GMT at Day 1, 11, 29, 91 and 181</title>
          <description>GMTs of vibriocidal antibody and anti-CT IgG concentrations at Days 1, 11, 29, 91, and 181.</description>
          <population>The subgroup examining long-term and specific functional immunogenicity was formed to examine specific behavior of Vaxchora based a smaller total sample size than the total study due to the complexity of the assays needed for the endpoints. As such, an analysis by lot would have rendered any examination severely underpowered and was not necessary due to the objective to examine Vaxchora vs placebo rather than the affect of lot on those endpoints.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVA GMT at Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="52" upper_limit="162"/>
                    <measurement group_id="O2" value="143" lower_limit="12" upper_limit="1728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA GMT at Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9922" lower_limit="4306" upper_limit="22865"/>
                    <measurement group_id="O2" value="320" lower_limit="6" upper_limit="16216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA GMT at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6170" lower_limit="3798" upper_limit="10025"/>
                    <measurement group_id="O2" value="127" lower_limit="10" upper_limit="1623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA GMT at Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560" lower_limit="322" upper_limit="975"/>
                    <measurement group_id="O2" value="127" lower_limit="10" upper_limit="1623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA GMT at Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386" lower_limit="211" upper_limit="703"/>
                    <measurement group_id="O2" value="53" lower_limit="8" upper_limit="348"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG GMT at Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445" lower_limit="405" upper_limit="489"/>
                    <measurement group_id="O2" value="951" lower_limit="296" upper_limit="3057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG GMT at Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1780" lower_limit="901" upper_limit="3517"/>
                    <measurement group_id="O2" value="800" lower_limit="319" upper_limit="2008"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG GMT at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2007" lower_limit="1075" upper_limit="3748"/>
                    <measurement group_id="O2" value="848" lower_limit="316" upper_limit="2275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG GMT at Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1276" lower_limit="771" upper_limit="2111"/>
                    <measurement group_id="O2" value="599" lower_limit="370" upper_limit="972"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG GMT at Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1116" lower_limit="687" upper_limit="1814"/>
                    <measurement group_id="O2" value="528" lower_limit="329" upper_limit="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVA and Anti-CT IgG Seroconversion at Day 1, 11, 29, 91 &amp; 181</title>
        <description>Proportion of subjects who demonstrated a ≥4-fold rise over baseline in vibriocidal antibody and anti-CT IgG concentration from baseline at Days 1, 11, 29, 91, and 181. Day 1 not reported as seroconversion on Day 1 not applicable.</description>
        <time_frame>Day 1 - 181</time_frame>
        <population>The subgroup examining long-term and specific functional immunogenicity was formed to examine specific behavior of Vaxchora based a smaller total sample size than the total study due to the complexity of the assays needed for the endpoints. As such, an analysis by lot would have rendered any examination severely underpowered and was not necessary due to the objective to examine Vaxchora vs placebo rather than the affect of lot on those endpoints.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo physiological saline</description>
          </group>
        </group_list>
        <measure>
          <title>SVA and Anti-CT IgG Seroconversion at Day 1, 11, 29, 91 &amp; 181</title>
          <description>Proportion of subjects who demonstrated a ≥4-fold rise over baseline in vibriocidal antibody and anti-CT IgG concentration from baseline at Days 1, 11, 29, 91, and 181. Day 1 not reported as seroconversion on Day 1 not applicable.</description>
          <population>The subgroup examining long-term and specific functional immunogenicity was formed to examine specific behavior of Vaxchora based a smaller total sample size than the total study due to the complexity of the assays needed for the endpoints. As such, an analysis by lot would have rendered any examination severely underpowered and was not necessary due to the objective to examine Vaxchora vs placebo rather than the affect of lot on those endpoints.</population>
          <units>% of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SVA Seroconversion at Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" lower_limit="71" upper_limit="99"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA Seroconversion at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96" lower_limit="80" upper_limit="100"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA Seroconversion at Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="48" upper_limit="86"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SVA Seroconversion at Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50" lower_limit="30" upper_limit="70"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG Seroconversion at Day 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="23" upper_limit="63"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG Seroconversion at Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="27" upper_limit="67"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG Seroconversion at Day 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="23" upper_limit="63"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CT IgG Seroconversion at Day 181</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="17" upper_limit="56"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, fever &amp; vomiting were collected from Day 1 - 8.&#xD;
Incidence and severity of unsolicited adverse events were collected till Day 29.</description>
        <time_frame>Day 1 - 29</time_frame>
        <population>Safety population - the population of randomized subjects who received study treatment and was analyzed according to the treatment actually received.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200 Lot A</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>PXVX0200 Lot B</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O3">
            <title>PXVX0200 Lot C</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O4">
            <title>PXVX0200 (Lot A, B and C)</title>
            <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension&#xD;
PXVX0200: comparing 3 lots of PXVX0200</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo physiological saline&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Incidence and severity of signs and symptoms of reactogenicity such as diarrhea, fever &amp; vomiting were collected from Day 1 - 8.&#xD;
Incidence and severity of unsolicited adverse events were collected till Day 29.</description>
          <population>Safety population - the population of randomized subjects who received study treatment and was analyzed according to the treatment actually received.</population>
          <units>% of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="904"/>
                <count group_id="O2" value="908"/>
                <count group_id="O3" value="922"/>
                <count group_id="O4" value="2734"/>
                <count group_id="O5" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>% of Subjects with any Reactogenicity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.99"/>
                    <measurement group_id="O2" value="50.44"/>
                    <measurement group_id="O3" value="52.28"/>
                    <measurement group_id="O4" value="51.90"/>
                    <measurement group_id="O5" value="43.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Diarrhea Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.31"/>
                    <measurement group_id="O2" value="3.96"/>
                    <measurement group_id="O3" value="3.36"/>
                    <measurement group_id="O4" value="3.88"/>
                    <measurement group_id="O5" value="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Fever Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77"/>
                    <measurement group_id="O2" value="0.77"/>
                    <measurement group_id="O3" value="0.33"/>
                    <measurement group_id="O4" value="0.62"/>
                    <measurement group_id="O5" value="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Nausea/Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.03"/>
                    <measurement group_id="O2" value="18.94"/>
                    <measurement group_id="O3" value="18.00"/>
                    <measurement group_id="O4" value="18.32"/>
                    <measurement group_id="O5" value="15.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>% of Subjects with Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.09"/>
                    <measurement group_id="O2" value="26.43"/>
                    <measurement group_id="O3" value="30.26"/>
                    <measurement group_id="O4" value="28.93"/>
                    <measurement group_id="O5" value="23.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots B and C</title>
        <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.</description>
        <time_frame>Day 11</time_frame>
        <population>The Immunogenicity Evaluable Population (IEP) comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200 Lot B</title>
            <description>A single dose PXVX0200; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>PXVX0200 Lot C</title>
            <description>A single dose PXVX0200; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots B and C</title>
          <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.</description>
          <population>The Immunogenicity Evaluable Population (IEP) comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity.</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="887"/>
                <count group_id="O2" value="909"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10034" lower_limit="8942" upper_limit="11260"/>
                    <measurement group_id="O2" value="9827" lower_limit="8770" upper_limit="11012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Lot B vs Lot C</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The GMT of each lot was required to be within ±50% of each other lot with 95% confidence. Specifically, the 95% CI around each pairwise ratio of GMTs was required to be within [0.67, 1.5].</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and C</title>
        <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.</description>
        <time_frame>Day 11</time_frame>
        <population>The Immunogenicity Evaluable Population (IEP) comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity.</population>
        <group_list>
          <group group_id="O1">
            <title>PXVX0200 Lot A</title>
            <description>A of single dose PXVX0200; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
          <group group_id="O2">
            <title>PXVX0200 Lot C</title>
            <description>A of single dose PXVX0200; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) at Day 11 for Vaccine Lots A and C</title>
          <description>The primary analysis consisted of three between-lot equivalence tests of serum vibriocidal antibody titer measured at Day 11. The GMT of each lot - µA, µB, and µC - was calculated by first log-transforming (base 10) the serum vibriocidal antibody titers, computing the means of the transformed data by lot, and then exponentiating the log-scale means to return to the original, untransformed scale. The resulting GMTs were combined to form three geometric mean ratios: µA/µB, µA/µC, and µB/µC.The ratios were required to be within +/- 50% of each other lot with 95% confidence, which implied that the limits of the 95% confidence interval on each pairwise GMR had to be within 0.67 - 1.5.</description>
          <population>The Immunogenicity Evaluable Population (IEP) comprises all randomized subjects who had evaluable vibriocidal antibody results from Day 11 and had no major protocol violations that affected immunogenicity.</population>
          <units>Geometric Mean Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="892"/>
                <count group_id="O2" value="909"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9220" lower_limit="8219" upper_limit="10343"/>
                    <measurement group_id="O2" value="9827" lower_limit="8770" upper_limit="11012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Lot A vs. Lot C</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>The GMT of each lot was required to be within ±50% of each other lot with 95% confidence. Specifically, the 95% CI around each pairwise ratio of GMTs was required to be within [0.67, 1.5].</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited AEs, serious adverse events (SAEs), medically attended events, and new onset of chronic medical conditions were assessed for 180 days post-vaccination.</time_frame>
      <desc>Totals presented are the number of subjects with at least one AE. Analysis of all cause mortality, SAEs and other serious events were performed for the safety population (N=2789) and not the randomized population. Only the SAEs were analyzed per lot while the analysis for the AEs was not completed for subjects that received each lot. This covers the entire safety of Vaxchora to provide the overall profile. The larger sample size afforded better estimates of risk for the observed events.</desc>
      <group_list>
        <group group_id="E1">
          <title>PXVX0200 Lot A</title>
          <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="E2">
          <title>PXVX0200 Lot B</title>
          <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="E3">
          <title>PXVX0200 Lot C</title>
          <description>PXVX0200 Single dose; liquid suspension after reconstitution with buffer; 1x10^9 CFU in a liquid suspension</description>
        </group>
        <group group_id="E4">
          <title>All PXVX0200 Lots</title>
          <description>All PXVX0200 Lots</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>Placebo physiological saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Jaw Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Stress Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="926"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="928"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="935"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="290" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="33" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="350"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="59" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="2789"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="350"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Cassie, Scientist, Clinical Research</name_or_title>
      <organization>Emergent BioSolutions Canada Inc.</organization>
      <phone>204-275-4589</phone>
      <email>dcassie@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

